Advertisement
National Stem Cell President, Michael Cohen, stated, "I am pleased toparticipate in this event which has focused much needed attention to twocritically important issues facing the stem cell / Regenerative Medicineindustry: the need for increasing and improving strategic collaborations amongthe key stakeholders namely, development stage biotech companies, academicInstitutions and government agencies, together with the attendant need todevelop and recruit trained scientific personnel to meet both current andfuture industrial demands. Failure to address these issues rapidly andeffectively within the U.S. risks the significant loss of intellectualproperty research and development and value to industrial sectors abroad."
Advertisement
The Stem Cell Partnering Series is a not-for-profit organization thatactively supports the development and sustainability of the stem cell industryby fostering business collaborations and career development.
For more information on National Stem Cell Holding, Inc. please contact usat the company website: www.nationalstemcell.com or www.pinksheets.com.
About National Stem Cell Holding, Inc.
National Stem Cell Holding, Inc. is a hybrid biotechnology company focusedon developing therapeutics based upon the use of human stem cells and theirderivatives. The term 'hybrid' refers to both the business model as well itsproduct line. The Company is developing a pipeline of proprietary stem celltherapeutics with particular focus on diabetes. Many of the currentlyincurable diseases associated with aging are caused by the degeneration ofspecific cell types in the body. These include but are not limited to: cancer,heart disease, diabetes, neurodegenerative diseases and auto immuneconditions. In addition to its work with stem cell therapeutics, the Companyis leveraging its commercial infrastructure and product developmentcapabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissueBank and IVF laboratory) and National Stem Cell Blood Laboratories Inc (cordblood banking program), and its affiliate, Decouverte Cosmetique, Inc.(cosmetics). The Company's investigational products are focused on theimprovement of the quality of life for patients and their families. TheCompany's multi-facetted R&D program has demonstrated results with over 10patent applications and multiple products ready to enter the market. TheCompany is headquartered in Mountainside, NJ and has facilities at multipleacademic institutions.
"Safe Harbor Statement"
Under The Private Securities Litigation Reform Act of 1995: The statementsin the press release that relate to the company's expectations with regard tothe future impact on the company's results from new products in developmentare forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. The results anticipated by any or all of theseforward-looking statements may not occur. The Company undertakes no obligationto publicly release the result of any revisions to these forward-lookingstatements that may be made to reflect events or circumstances after the datehereof, or to reflect the occurrence of unanticipated events or changes in theCompany's plans or expectations.Contact: Michael Cohen Phone: (212)792-6188 [email protected]
SOURCE National Stem Cell Holding, Inc.
